• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » JNJ continues to pay hefty integration charges on Synthes deal

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 By Brian Johnson

JNJ continues to pay hefty integration charges on Synthes deal

The cost of integrating its most recent mega-merger are adding up for healthcare giant Johnson & Johnson (NYSE:JNJ), which this week revealed another $167 million hit to the bottom line from its $21.3 billion buyout of Synthes in the winter of 2012.

The latest charge brings the total price tag of integrating the companies to $800 million over the last 7 quarters, almost as much as the $899 million in special charges the company paid in 2012, the year it closed the deal.

During its earnings call with analysts this week, Deutsche Bank analyst Kristen Stewart expressed surprise over the continuing drag on the business.

"We’ve seen the special charges for Synthes continue for longer than I would have anticipated," Stewart told J&J execs during the call. "I’ve just been surprised by the magnitude and by how long we’ve been seeing that.”

Stewart asked the officials when they expect to fully integrate Synthes and put a stop to related 1-time charges. CFO Dominic Caruso sought to reassure, saying that the special charges were almost completed.

"Well, we are very careful to integrate this business in a way that wouldn’t be disruptive to our customers, and we made sure that that was our first priority," Caruso said. "There are a number of sites that we have to consolidate. These are 2 very large businesses, as you can imagine. So these integration activities are winding down and we should see less of the special charges going forward. And I would say that we’re very close to actually completing the full integration of Synthes."

The company’s DePuy Orthopaedics franchise, which has been tasked with integrating the Synthes business, announced this summer that had cut cut more than 400 jobs, or about 2% of its 23,000-employee workforce.

Company spokeswoman Lorie Gawreluk told MassDevice.com at the time that the company was "transforming our operating model to enhance our ability to offer broader portfolio solutions to hospitals, provide superior product innovation and expert service to surgeons, reinforce our organizational capabilities and align our cost structure to our evolving environment."

J&J’s troubles integrating the Swiss orthopedics firm may prove to be a bellwether for several other large medtech firms with pending mega-mergers: Zimmer (NYSE:ZMH) and its $13 billion union with orthopedics rival Biomet as well as Medtronic (NYSE:MDT) and its high-profile, $43 billion buyout of Covidien (NYSE:COV).


Filed Under: Mergers & Acquisitions, News Well Tagged With: Biomet, Covidien, depuysynthes, Johnson and Johnson, Zimmer Biomet

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy